The DOI matches its Crossref record.
A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis.
Open accessAbstract
A trial of n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis has been conducted over a 5 year period. Ambulant patients (312) with acute remitting disease were randomly allocated to treatment or placebo. Both groups were given dietary advice to increase the intake of n-6 polyunsaturated fatty acids and the treatment group in addition received capsules containing n-3 polyunsaturated fatty acids. Analysis of clinical outcome at the end of 2 years of treatment was made in terms of the duration, frequency and severity of relapses and the number of patients who had improved or remained unchanged. The results showed no significant difference at the usual 95% confidence limits but there was a trend in favour of the group treated with n-3 polyunsaturated fatty acids in all parameters examined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors
Ascherio, A., & Munger, K. L. (2007) · Annals of Neurology · doi:10.1002/ana.21141 · Cited by 714
Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy.
Ghasemi, N., Razavi, S., & Nikzad, E. (2016) · PubMed · doi:10.22074/cellj.2016.4867 · Cited by 685
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub3 · Cited by 630
Abedi, E., & Sahari, M. A. (2014) · Food Science & Nutrition · doi:10.1002/fsn3.121 · Cited by 584
ESPEN guideline clinical nutrition in neurology
Burgos, R., Bretón, I., Cereda, E., Desport, J. C., Dziewas, R., Genton, L., Gomes, F., Jésus, P., Leischker, A., Muscaritoli, M., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.003 · Cited by 571
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub4 · Cited by 405
n‐3 Omega fatty acids: a review of current knowledge
Gogus, U., & Smith, C. (2010) · International Journal of Food Science & Technology · doi:10.1111/j.1365-2621.2009.02151.x · Cited by 358
Steffens, W. (1997) · Aquaculture · doi:10.1016/s0044-8486(96)01493-7 · Cited by 353
Neurological Benefits of Omega-3 Fatty Acids
Dyall, S. C., & Michael-Titus, A. T. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8036-z · Cited by 311
The Influence of Dietary Fatty Acids on Immune Responses
Radzikowska, U., Rinaldi, A. O., Çelebi Sözener, Z., Karaguzel, D., Wojcik, M., Cypryk, K., Akdis, M., Akdis, C. A., & Sokolowska, M. (2019) · Nutrients · doi:10.3390/nu11122990 · Cited by 306
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., Summerbell, C. D., Worthington, H. V., Song, F., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub5 · Cited by 295
Current Clinical Applications of Ω‐6 and Ω‐3 Fatty Acids
Lee, S., Gura, K. M., Kim, S., Arsenault, D. A., Bistrian, B. R., & Puder, M. (2006) · Nutrition in Clinical Practice · doi:10.1177/0115426506021004323 · Cited by 100
Metadata
- Authors
- Bates, D., Cartlidge, N. E., French, J. M., Jackson, M. J., Nightingale, S., Shaw, D. A., Smith, S., Woo, E., Hawkins, S. A., & Millar, J. H.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 1989-01-01
- Volume
- 52
- Issue
- 1
- Pages
- 18-22
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2108765995
- Cited by
- 181
- References
- 0
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.